NEOS Investment Management LLC Has $1.20 Million Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

NEOS Investment Management LLC increased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 199.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,343 shares of the company’s stock after buying an additional 29,542 shares during the period. NEOS Investment Management LLC owned 0.08% of Structure Therapeutics worth $1,203,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd increased its stake in shares of Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares during the last quarter. GAMMA Investing LLC increased its position in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after buying an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in Structure Therapeutics in the fourth quarter valued at approximately $40,000. Assetmark Inc. lifted its position in shares of Structure Therapeutics by 72.3% in the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock valued at $62,000 after buying an additional 953 shares during the last quarter. Finally, Jones Financial Companies Lllp lifted its position in shares of Structure Therapeutics by 29.8% in the fourth quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company’s stock valued at $115,000 after buying an additional 971 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

GPCR has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, William Blair initiated coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Trading Down 0.9 %

NASDAQ GPCR opened at $19.77 on Friday. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -26.72 and a beta of -2.37. The company has a 50 day moving average of $24.19 and a 200-day moving average of $31.22. Structure Therapeutics Inc. has a 1-year low of $18.87 and a 1-year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, equities research analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.